Sign in
CompletedNo phase

Microbiome and Premature Ovarian Insufficiency

Key facts

Who runs it
Westlake University
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
39 people enrolled
Started
13 May 2025
Ended
18 Dec 2025
Type of study
Observational, 2 groups
Record updated
26 June 2026

Who can take part

Age
20 years to 40 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • (For POI patients)
  • Women aged 20 to 40 years at screening visit
  • Clinical diagnosis of premature ovarian insufficiency (based on diagnostic criteria: 25 < FSH ≤ 40 IU/L, reduced follicle count and abnormal follicle development by ultrasound)
  • Able to provide informed consent; (For healthy volunteers)
  • Age (±2 years) and sex-matched healthy control individuals for each POI patient
  • Able to provide informed consent

Who cannot take part

  • Use of hormone therapy (such as HRT) within the past 6 months
  • Use of antibiotics in the past 3 months before sample collection
  • Use of hormone therapy (e.g., loratadine, oral contraceptives, etc.) within the past 6 months
  • Use of antibiotics in the past 3 months before sample collection
  • Family history of premature ovarian insufficiency
  • Serious illness (e.g., heart failure or malignancy)
  • Smoking more than 15 cigarettes per day or history of alcohol or drug addiction
  • Inflammatory gastrointestinal diseases
  • Chronic diseases that may affect the gut microbiota (e.g., diabetes, cirrhosis, or cardiovascular disease)
  • Blood or autoimmune diseases, or use of immunosuppressants in the past 3 months
  • Have a history of infertility or recurrent miscarriage
  • Inflammatory gastrointestinal diseases
  • Smoking more than 15 cigarettes per day or history of alcohol or drug addiction
  • Chronic diseases that may affect the gut microbiota (e.g., diabetes, cirrhosis, or cardiovascular disease)
  • Blood or autoimmune diseases, or use of immunosuppressants in the past 3 months
  • (For POI patients)
  • Chronic constipation; (For healthy volunteers)
  • Pregnant or breastfeeding
  • Chronic constipation
  • Participating in other clinical trials

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study investigates the differences in gut and vaginal microbiota between women with premature ovarian insufficiency (POI) and healthy volunteers. POI refers to the reduction in ovarian function before the age of 40, leading to irregular or absent menstruation and decreased estrogen levels, which can significantly affect women's reproductive and overall health. Recent research has suggested that gut microorganisms may influence the balance of steroid hormones through various metabolic pathways. Additionally, certain vaginal bacteria appear enriched in patients with POI, but whether these microorganisms directly impact ovarian function, and how, remains unclear. This study also seeks to address the underexplored role of fungi within the human microbiome. To comprehensively compare differences in gut and vaginal microbiota, the study will recruit 20 women with POI and 20 healthy controls. Both demographic and clinical information will be collected, along with biological samples including blood, urine, stool, and vaginal swabs.

The 2 groups in the trial

  • POI

    Premature ovarian insufficiency

  • CTL

    Healthy control

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Case-Control Study of Gut and Vaginal Microbiota Differences Between Premature Ovarian Insufficiency Patients and Healthy Controls
Record updated
26 June 2026